Scarica l'app Stockscreener
4.25
1.62%
-0.07
Dopo l'orario di chiusura:
4.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MYGN Giù?
Forum
Previsione
Frazionamento azionario
Myriad Genetics Inc Borsa (MYGN) Ultime notizie
Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan - Stock Titan
Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan - Stock Titan
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Insider Sell Alert: Rashmi Kumar Sells 15,000 Shares of Myriad G - GuruFocus
Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Should You Add Myriad Genetics Stock to Your Portfolio Right Now? - Yahoo Finance
[144] MYRIAD GENETICS INC SEC Filing - Stock Titan
Director at Myriad Genetics (MYGN) receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) director awarded 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis - Stock Titan
[Form 4] MYRIAD GENETICS INC Insider Trading Activity - Stock Titan
Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units - Stock Titan
Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro - Stock Titan
Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award - Stock Titan
Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans - Stock Titan
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Myriad Genetics Inc Annual Shareholders Meeting Transcript - GuruFocus
MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - ChartMill
Dr. Crystal Nelson Explains How Genetic Testing Is Transforming Mental Health Medication Treatment on YourUpdateTV - The Manila Times
Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units - Stock Titan
Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report - Stock Titan
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026 - TradingView
Myriad Genetics names Raj Jampa as chief technology officer - Investing.com UK
Myriad Genetics Names Raj Jampa as New Chief Technology Officer - The Globe and Mail
Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer - Moomoo
Myriad Genetics names Raj Jampa as chief technology officer By Investing.com - Investing.com Canada
Statistics Show that Patients Want More Personalized Mental Health Care - KOIN.com
Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates - Stocktwits
Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus - AD HOC NEWS
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - The Globe and Mail
Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock - Yahoo Finance
MYGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Myriad Genetics’ Precise MRD Assay Data Presented at ASCO 2026 Shows Potential for Assessing Treatment Response and Monitoring Recurrence in Cancer Patients - geneonline.com
Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting - marketscreener.com
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting - The Manila Times
MYGN Cancer Care Strategy: What's Driving 2026 Growth Plans - Yahoo Finance
Myriad Genetics (MYGN) Unveils Innovative Prolaris + AI Test for Prostate Cancer - GuruFocus
Myriad Genetics launches Prolaris + AI prostate cancer test - Investing.com UK
Myriad Genetics launches Prolaris + AI prostate cancer test By Investing.com - Investing.com Nigeria
Myriad Genetics Launches Prolaris® + AI - TradingView
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) - marketscreener.com
Myriad Genetics Launches Prolaris Plus AI Test Combining Genomics And Digital Pathology Artificial Intelligence - marketscreener.com
AI-enhanced prostate cancer test to guide active surveillance decisions - Stock Titan
MYGN Technical Analysis & Stock Price Forecast - Intellectia AI
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35 - MSN
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN) - MSN
Myriad Genetics | 5/22/26 - ktnv.com
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships - Traders Union
‘American Idol’ Star Speaks Out on Health Issues 17 Years After Show Appearance - Parade
0.56%
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):